Two Different, Mutually Exclusively Distributed, Mutations in Ovarian and Peritoneal Tumor Tissues of a Serous Ovarian Cancer Patient: Indicative for Tumor Origin?
Overview
Authors
Affiliations
High-grade serous ovarian cancer (HGSOC) is characterized by a mutation rate of up to 96.7% and associated with a more aggressive tumor biology. The origin of HGSOC is thought to arise either from fallopian tube secretory cells or the ovarian surface epithelium/inclusion cysts, the former with more evidence. Peritoneal tumor spread is heterogeneous, either excessive in the peritoneum (with miliary appearance) or more confined to the ovaries with only few (bigger and exophytically growing) peritoneal implants. Using RNA sequencing and DNA digital droplet polymerase chain reaction (PCR), we identified two different functional mutations in one HGSOC patient: one exclusively in the ovarian tumor mass and the other exclusively in ascites tumor cells, peritoneal tumor masses, and a lymph node metastasis. In blood, both mutations could be detected, the one from the peritoneal tumors with much higher frequency, presumably because of the higher tumor load. We conclude that this mutually exclusive distribution of two different mutations in different tumor tissues indicates the development of two independent carcinomas in the peritoneal cavity, probably one originating from a precancerous lesion in the fallopian tube and the other from the ovaries. In addition, in the patient's ascites CD45 and EpCAM, double-positive cells were found-proliferating but testing negative for the above-mentioned mutations. This mutually exclusive distribution of two mutations is probably further evidence that HGSOC can originate either from the fallopian tube or (more seldom) the ovaries, the former more prone for excessive peritoneal tumor spread.
Application of single cell sequencing technology in ovarian cancer research (review).
Yuan Q, Lv N, Chen Q, Shen S, Wang Y, Tong J Funct Integr Genomics. 2024; 24(5):144.
PMID: 39196391 PMC: 11358195. DOI: 10.1007/s10142-024-01432-w.
Zhang J, Kong X, Yang H, Mohibi S, Lucchesi C, Zhang W Cancers (Basel). 2024; 16(1).
PMID: 38201656 PMC: 10778559. DOI: 10.3390/cancers16010229.
Hybrid/Atypical Forms of Circulating Tumor Cells: Current State of the Art.
Kaigorodova E, Kozik A, Zavaruev I, Grishchenko M Biochemistry (Mosc). 2022; 87(4):380-390.
PMID: 35527376 PMC: 8993035. DOI: 10.1134/S0006297922040071.
Pils D, Steindl E, Bachmayr-Heyda A, Dekan S, Aust S Cancers (Basel). 2020; 12(8).
PMID: 32806596 PMC: 7464642. DOI: 10.3390/cancers12082257.
Bekos C, Muqaku B, Dekan S, Horvat R, Polterauer S, Gerner C Cancers (Basel). 2019; 11(5).
PMID: 31137558 PMC: 6562934. DOI: 10.3390/cancers11050698.